文献速递免疫规划传染病防控与疫情报告

实体器官与造血干细胞移植受者早期接种麻疹减毒活疫苗的安全性与有效性综述

Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients.
PubMed 文献 · Vaccine · 2021-05-12

本文系统综述了实体器官移植(SOT)后及造血干细胞移植(HSCT)后不足两年接种麻疹减毒活疫苗的安全性与有效性。纳入10项研究,SOT后单剂血清转化率41%–100%、两剂73%–100%;HSCT后不足两年单剂33%–100%、两剂100%;所有研究均认为接种安全,无疫苗株感染或相关不良事件。结论认为早期接种可能有效且耐受良好,可考虑用于麻疹传播增加或暴发时的特定移植受者。

要点

  • SOT后接种麻疹疫苗单剂血清转化率41%–100%,两剂73%–100%。
  • HSCT后不足两年接种单剂血清转化率33%–100%,两剂达100%。
  • 所有纳入研究中接种均安全,无疫苗株感染或相关不良事件。

核心结论

  • SOT后及HSCT后不足两年接种麻疹疫苗的数据有限,但现有数据提示有效且耐受良好。
  • 在麻疹传播增加或暴发时,可考虑对特定SOT和HSCT受者早期接种麻疹疫苗。

研究设计与样本

  • 本文为综述,检索PubMed和EMBASE自最早可获取日期至2019年10月,纳入报告SOT后或HSCT后不足两年接种麻疹疫苗安全性与有效性的研究。
  • 共纳入10项研究,其中6项评估SOT后接种有效性,4项评估HSCT后不足两年接种有效性。

主要发现

  • 6项SOT后接种研究中,单剂血清转化率41%–100%,两剂73%–100%。
  • 4项HSCT后不足两年接种研究中,单剂血清转化率33%–100%,两剂100%。
  • 所有研究中移植后接种麻疹疫苗均被认为安全,无疫苗株感染病例,无与接种相关的不良事件。

关键数值与推荐

  • SOT后麻疹疫苗单剂血清转化率41%–100%,两剂73%–100%。
  • HSCT后不足两年麻疹疫苗单剂血清转化率33%–100%,两剂100%。
  • 所有纳入研究均报告移植后接种安全,无疫苗株感染及接种相关不良事件。

临床怎么用

  • 当前指南推荐HSCT后两年接种麻疹疫苗、SOT后一般禁忌,新数据可能改变现行指南与实践。
  • 在麻疹传播增加或暴发时,可考虑对特定SOT和HSCT受者早期接种麻疹疫苗。

局限性

  • 移植后接种麻疹疫苗的数据 scarce(稀缺),仅纳入10项研究。
  • 早期接种的有效性与安全性证据仍有限,需更多研究支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Vaccination with the live attenuated measles vaccine is currently recommended two years after hematopoietic stem cell transplantation (HSCT) and generally contraindicated after solid organ transplantation (SOT) due to safety concerns. However, in the last few years new data on the administration of the measles vaccine to HSCT recipients less two years post-transplantation and to SOT recipients have become available. This new data may change current guidelines and practices. The objective of this review is to provide an overview of the current data on the safety and efficacy of early measles vaccination for HSCT- and SOT recipients. METHOD: PubMed and EMBASE were searched from the earliest date available through October 2019 to identify all research that reported on the safety and efficacy of measles vaccination after SOT or less than two years after HSCT. RESULTS: A total of ten studies was included in this review. In the six studies that evaluated the efficacy of measles vaccination after SOT, seroconversion rates ranged from 41 to 100% after one dose and 73 to 100% after two doses. In the four studies that evaluated the efficacy of measles vaccination less than two years after HSCT, seroconversion rates ranged from 33 to 100% after one dose and 100% after two doses. In all studies, the administration of the measles vaccine after transplantation was considered to be safe. There were no cases of infection with the attenuated vaccine strain, and there were no adverse events related to the vaccination. CONCLUSION: Data on the administration of the measles vaccine after SOT and less than two years after HSCT is scarce. However, the current data available suggest that it is efficacious and well tolerable. Therefore, early measles vaccination could be considered in selected groups of SOT- and HSCT recipients during increased measles transmission or an outbreak setting.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Groeneweg L, Loeffen YGT, Versluys AB, et al. Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients. Vaccine. 2021. PMID: 33992440. doi:10.1016/j.vaccine.2021.04.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。